Immix Biopharma, Inc.

Immix Biopharma, Inc.

Biotechnology • Healthcare • Los Angeles, CA, United States • IMMX (NCM)

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

310 651 8041 11400 West Olympic Boulevard, Los Angeles, CA 90064, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Yahoo Finance
Yahoo Finance • Dec 9
Immix Biopharma, Inc. Closes $93.7 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative
Quiver Quantitative • Dec 9
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition (IMMX) - Seeking Alpha
Seeking Alpha • Dec 11
Immix Biopharma (IMMX) sets price for upsized $100M stock and pre-funded warrant offering - Stock Titan
Stock Titan • Dec 7
Immix Biopharma (NASDAQ:IMMX) Stock Rating Upgraded by Wall Street Zen - MarketBeat
MarketBeat • Dec 13

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Immix Biopharma, Inc. had layoffs?
No layoff events have been recorded for Immix Biopharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Immix Biopharma, Inc. have?
Immix Biopharma, Inc. has approximately 18 employees.
What industry is Immix Biopharma, Inc. in?
Immix Biopharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Immix Biopharma, Inc. a publicly traded company?
Yes, Immix Biopharma, Inc. is publicly traded under the ticker symbol IMMX on the NCM. The company has a market capitalization of approximately $0.29 billion.
Where is Immix Biopharma, Inc. headquartered?
Immix Biopharma, Inc. is headquartered in Los Angeles, CA, United States at 11400 West Olympic Boulevard, Los Angeles, CA 90064, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.